Interleukin 18 (IL-18) in synergy with IL-2 induces lethal lung injury in mice: a potential role for cytokines, chemokines, and natural killer cells in the pathogenesis of interstitial pneumonia.
Interleukin 18 (IL-18) was discovered as an interferon-gamma (IFN-gamma)-inducing factor and plays important roles in natural killer (NK) cell activation. IL-18 also induces proinflammatory cytokines; chemokines; helper T-cell 2 (T(H)2) cytokines (eg, IL-4, IL-13); and immunoglobulin E (Ig-E) and IgG1 production. The combination of IL-18 plus IL-2 or IL-12 up-regulates IFN-gamma gene expression and NK cytotoxicity and has synergistic antitumor activity in vivo and in vitro. Here it is reported that daily administration of IL-18 with IL-2, but not of IL-18 or IL-2 alone, induces lethal lung injury in normal mice, but not in IL-18 receptor alpha (IL-1 receptor-related protein)-deficient (IL-18 receptor alpha(-/-)) mice. Marked interstitial infiltration of lymphocytes, composed mainly of NK cells, was found in the lungs of IL-18/IL-2-treated mice. Increased cytokine and chemokine levels were observed in the sera and lungs of IL-18/IL-2-treated mice. Administration of IL-18/IL-2 was also lethal to mice treated with a metalloproteinase inhibitor, which inhibited tumor necrosis factor-alpha and Fas-ligand release. While IFN-gamma(-/-) mice were partially resistant to the treatment, IL-4(-/-), IL-13(-/-), IL-4/IL-13(-/-), and Stat6(-/-) mice were sensitive to IL-18/IL-2, indicating that these genes were not involved in the host response. The lethal effect by IL-18/IL-2 was completely eliminated in severe combined immunodeficient mice pretreated with antiasialo-GM1 antibody and normal mice pretreated with anti-NK1.1 but not with anti-CD4 or anti-CD8, monoclonal antibody. These results suggest that specific cytokines, chemokines, and NK cells are involved in the pathogenesis of interstitial pneumonia. These results suggest that the clinical use of this interleukin may result in unexpected physiological consequences.
Okamoto
Masaki
M
Department of Internal Medicine, Kurume University School of Medicine, Japan.
Kato
Seiya
S
Oizumi
Kotaro
K
Kinoshita
Masaharu
M
Inoue
Yoshimasa
Y
Hoshino
Katsuaki
K
Akira
Shizuo
S
McKenzie
Andrew N J
AN
Young
Howard A
HA
Hoshino
Tomoaki
T
D000818:Animals; D018925:Chemokines / Q000235:genetics / Q000378:metabolism; D002633:Chemotaxis / Q000187:drug effects; D016207:Cytokines / Q000187:drug effects / Q000235:genetics / Q000378:metabolism; D004357:Drug Synergism; D020382:Interleukin-18 / Q000008:administration & dosage / Q000633:toxicity*; D007376:Interleukin-2 / Q000008:administration & dosage / Q000633:toxicity*; D007694:Killer Cells, Natural / Q000276:immunology; D008168:Lung / Q000187:drug effects* / Q000473:pathology; D017563:Lung Diseases, Interstitial / Q000209:etiology* / Q000473:pathology; D051379:Mice; D018345:Mice, Knockout; D016513:Mice, SCID; D015996:Survival Rate
D018925:Chemokines; D016207:Cytokines; D020382:Interleukin-18; D007376:Interleukin-2